Skip to main content
. 2014 Sep 24;6(2):182–191. doi: 10.1111/jdi.12282

Table 2.

Change in secondary endpoints from baseline to weeks 12 and 24

Mean change from baseline (week 12) Mean change from baseline (week 24)
Sitagliptin α-Glucosidase inhibitor P-value* Sitagliptin α-Glucosidase inhibitor P-value*
Glycoalbumin (%) −2.4 (−2.9 to −2.0) −0.74 (−1.2 to −0.29) <0.0001 −2.5 (−3.0 to −1.9) −1.1 (−1.8 to −0.31) 0.0026
1,5-AG (μmol/L) 21.6 (16.7 to 26.5) 28.9 (21.9 to 35.9) 0.089 23.2 (16.8 to 29.6) 32.6 (24.5 to 40.8) 0.072
Fasting plasma glucose (mmol/L) −0.60 (−1.1 to −0.092) 0.26 (−0.16 to 0.68) 0.010 −0.54 (−1.0 to −0.066) −0.15 (−0.60 to 0.29) 0.24
Fasting insulin (pmol/L) 6.7 (−5.7 to 18.9) 5.6 (−9.4 to 20.6) 0.91 −0.0088 (−10.6 to 10.6) −3.4 (−15.0 to 8.3) 0.67
Fasting C-peptide (nmol/L) 0.061 (−0.033 to 0.15) 0.032 (−0.061 to 0.13) 0.66 0.041 (−0.042 to 0.12) −0.010 (−0.082 to 0.61) 0.35
Fasting proinsulin-to-insulin ratio −0.0057 (−0.068 to 0.056) −0.031 (−0.086 to 0.025) 0.55 −0.041 (−0.11 to 0.027) 0.028 (−0.043 to 0.10) 0.16
HOMA-β 10.8 (6.0 to 15.6) −2.4 (−16.2 to 11.4) 0.072 8.9 (2.7 to 15.2) −0.60 (−9.2 to 8.0) 0.078
HOMA-IR −0.0094 (−1.0 to 1.0) 0.57 (−0.32 to 1.5) 0.39 −0.38 (−1.4 to 0.64) −0.12 (−0.91 to 0.67) 0.68
Bodyweight (kg) 0.25 (−0.12 to 0.62) −0.39 (−0.68 to −0.093) 0.0079 0.47 (−0.041 to 0.99) −0.60 (−1.0 to −0.16) 0.0021
Systolic blood pressure (mmHg) 1.4 (−2.2 to 5.1) 1.0 (−1.8 to 3.9) 0.87 1.6 (−1.9 to 5.0) 0.059 (−3.7 to 3.8) 0.55
Diastolic blood pressure (mmHg) −0.47 (−2.6 to 1.7) 0.67 (−1.9 to 3.2) 0.49 −0.38 (−2.2 to 1.4) 0.80 (−2.8 to 4.4) 0.55
Heart rate (beats per min) 1.5 (−1.2 to 4.3) −1.9 (−4.0 to 0.30) 0.054 0.67 (−2.0 to 3.3) −2.4 (−5.3 to 0.56) 0.12
Total cholesterol (mmol/L) −0.13 (−0.35 to 0.087) 0.21 (0.065 to 0.36) 0.010 −0.11 (−0.34 to 0.11) 0.18 (0.044 to 0.32) 0.025
LDL cholesterol (mmol/L) 0.0066 (−0.15 to 0.16) 0.21 (0.077 to 0.35) 0.047 −0.013 (−0.19 to 0.16) 0.19 (0.060 to 0.31) 0.065
HDL cholesterol (mmol/L) −0.0024 (−0.044 to 0.039) −0.012 (−0.058 to 0.034) 0.76 0.025 (−0.33 to 0.084) −0.0025 (−0.047 to 0.042) 0.45
Triglycerides (mmol/L) −0.050 (−0.28 to 0.18) 0.010 (−0.18 to 0.20) 0.69 −0.11 (−0.37 to 0.15) −0.17 (−0.34 to −0.0076) 0.68
Non-HDL cholesterol (mmol/L) −0.13 (−0.34 to 0.078) 0.22 (0.090 to 0.36) 0.0050 −0.13 (−0.35 to 0.093) 0.18 (0.051 to 0.32) 0.015

Changes from baseline to week 12 or week 24 are expressed as least-squares mean change (95% confidence interval).

*

P-value was calculated by comparing the difference from baseline between the sitagliptin and α-glucosidase inhibitor groups. HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-β, homoeostasis model assessment of β-cell function; HOMA-IR, homoeostasis model assessment of insulin resistance.